Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 3, 2010, Pages 1087-1095

  Damaj, M Imad ^a   Grabus, Sheri D ^a   Navarro, Hernan A ^b   Vann, Robert E ^a   Warner, Jonathan A ^a   King, Lindsey S ^a   Wiley, Jenny L ^a   Blough, Bruce E ^b   Lukas, Ronald J ^c   Carroll, F Ivy ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b RTI INTERNATIONAL   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DRUG METABOLITE; RADAFAXINE; DOPAMINE UPTAKE INHIBITOR; NICOTINE; NICOTINIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFECT; ENANTIOMER; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; SMOKING CESSATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; DISCRIMINATION LEARNING; DRUG EFFECTS; EMOTION; HYDROXYLATION; HYPERALGESIA; INSTITUTE FOR CANCER RESEARCH MOUSE; INSTRUMENTAL CONDITIONING; PERCEPTIVE DISCRIMINATION; PSYCHOLOGY; REWARD; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BUPROPION; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DISCRIMINATION LEARNING; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMOTIONS; HYDROXYLATION; HYPERALGESIA; MICE; MICE, INBRED ICR; NICOTINE; NICOTINIC AGONISTS; REWARD; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 77956253225     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.166850     Document Type: Article

References (28)

1. Bondarev ML, Bondareva TS, Young R, and Glennon RA (2003) Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 474:85-93.
2. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, and Ferris RM (1994) Evidence that the acute behavioral and electrophysiological effects of bupropion (Welbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11:133-141.
3. Cooper TB, Suckow RF, and Glassman A (1984) Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. J Pharm Sci 73:1104-1107.
4. Cryan JF, Bruijnzeel AW, Skjei KL, and Markou A (2003) Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168:347-358.
5. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, and Martin BR (2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66:675-682.
6. Dwoskin LP, Rauhut AS, King-Pospisil KA, and Bardo MT (2006) Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12:178-207.
7. Findlay JW, Van Wyck Fleet J, Smith PG, Butz RF, Hinton ML, Blum MR, and Schroeder DH (1981) Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 21:127-135.
8. Fryer JD and Lukas RJ (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288:88-92.
9. Golden RN, De Vane CL, Laizure SC, Rudorfer MV, Sherer MA, and Potter WZ (1988) Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 45:145-149.
10. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, and Johnston JA (1997) Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 37:737-743. (Pubitemid 27449283)
11. Jackson KJ, Martin BR, Changeux JP, and Damaj MI (2008) Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther 325:302-312.
12. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, and Varenicline Phase 3 Study Group (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56-63.
13. Kota D, Martin BR, Robinson SE, and Damaj MI (2007) Nicotine dependence and reward differ between adolescent and adult male mice. J Pharmacol Exp Ther 322:399-407.
14. Malin DH, Lake JR, Smith TD, Khambati HN, Meyers-Paal RL, Montellano AL, Jennings RE, Erwin DS, Presley SE, and Perales BA (2006) Bupropion attenuates nicotine abstinence syndrome in the rat. Psychopharmacology 184:494-503.
15. Martin P, Massol J, Colin JN, Lacomblez L, and Puech AJ (1990) Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 23:187-194.
16. 3H]dopamine and from rat hippocampal slices preloaded with [3H]norepinephrine. J Pharmacol Exp Ther 302:1113-1122.
17. Paterson NE (2009) Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights. Eur J Pharmacol 603:1-11.
18. Portugal GS and Gould TJ (2007) Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning. Pharmacol Biochem Behav 88:179-187.
19. Salas R, Sturm R, Boulter J, and De Biasi M (2009) Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. J Neurosci 29:3014-3018.
20. Slemmer JE, Martin BR, and Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321-327.
21. Suckow RF, Smith TM, Perumal AS, and Cooper TB (1986) Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs. Drug Metab Dispos 14:692-697.
22. Tallarida RJ and Murray RB (1987) Manual of Pharmacological Calculations with Computer Programs, Springer-Verlag, New York.
23. Terry P and Katz JL (1997) Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats. Psychopharmacology 134:201-212.
24. Welch RM, Lai AA, and Schroeder DH (1987) Pharmacological significance of the species differences in bupropion metabolism. Xenobiotica 17:287-298.
25. West R, Baker CL, Cappelleri JC, and Bushmakin AG (2008) Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology 197:371-377.
26. Wiley JL, Lavecchia KL, Martin BR, and Damaj MI (2002) Nicotine-like discriminative stimulus effects of bupropion in rats. Exp Clin Psychopharmacol 10:129-135.
27. Wing VC and Shoaib M (2007) Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. Psychopharmacology 195:303-313.
28. Young R and Glennon RA (2002) Nicotine and bupropion share a similar discriminative stimulus effect. Eur J Pharmacol 443:113-118.